ARCHIVES

FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says.

This article is from The Cancer Letter archive.

Vol. 31 No. 13 | April 1, 2005

Download PDF Visit The Full Archive

Related Articles

NCI, Groups Disagree Over repayment, McIntyre: NCA Could Examine Relationship of Groups To NCI

December 9, 1994

Army Breast Cancer Program Seeks Grants Applicants

May 17, 1996

Five Group Chairs Discuss Mergers In A Q&A

March 11, 2011

Senate Committee Blocks Effort To Overturn Organ Systems Changes

December 10, 1982

Final Issue of ‘76

December 10, 1976

Cetuximab Plus Irinotecan Increases PFS In Metastatic Colorectal Cancer, EPIC Finds

April 27, 2007